Make an enquiry
Refer a patient
Patient Portal
HCP Logout

We noticed you are on our AU page. Want to switch regions? Choose from the options:

UK
ES
Find a centre
Find a doctor
Make an enquiry
Refer a patient

We noticed you are on our AU page. Want to switch regions? Choose from the options:

UK
ES
Find a centre
Find a doctor
2024-02-12T00:00:00.000+00:00
Ongoing

BeiGene BGB-11417-301

BeiGene BGB-11417-301
Lymphoma

A phase 3, open-label, randomized study of Sonrotoclax (BGB-11417) plus Zanubrutinib (BGB-3111) compared with Venetoclax plus Obinutuzumab in patients with previously untreated chronic lymphocytic leukemia

A phase 3, open-label, randomized study of Sonrotoclax (BGB-11417) plus Zanubrutinib (BGB-3111) compared with Venetoclax plus Obinutuzumab in patients with previously untreated chronic lymphocytic leukemia

Trial overview

Clinical Area

Malignant Haemotology

Disease / Condition

Lymphoma

Study Phase

III

Trial Identifiers

Registration number: NCT06073821

https://clinicaltrials.gov/study/NCT06073821

GenesisCare Location(s)

GenesisCare North Shore

GenesisCare North Shore :::
Principal Investigator(s)

 Dr David Kilman

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.